Navigation Links
New cell transplantation technique restores insulin production in diabetics

Researchers are using a new cell transplantation technique to restore the cells that produce insulin in patients with type 1 diabetes. The method is minimally invasive, with few complications. The study was presented today at the annual meeting of the Radiological Society of North America (RSNA).

"We used ultrasound guidance to inject donor cells into the portal vein of diabetic patients, which is accessed through the skin," said co-author Saravanan Krishnamoorthy, M.D., radiology resident at the University of Minnesota in Minneapolis. "This is a safe method of cell transplantation that could potentially become a same-day procedure."

In type 1 diabetes, the body does not produce insulin. This typically results from the destruction of insulin-producing islet beta cells in the pancreas. Insulin is necessary to metabolize sugar, which is the basic fuel that all cells need.

With this minimally invasive technique, donor islet cells are injected into diabetic patients so that the new, healthy islet cells can restore insulin production, essentially stopping the progression of the disease. The study included 13 patients with poorly controlled type 1 diabetes. Fifteen islet cell transplants were completed-two patients underwent two procedures to achieve correct needle placement.

"We used a steroid-free protocol to suppress the immune system, so that the body accepted the transplanted cells," Dr. Krishnamoorthy said. "We also developed a 'sandwich technique' to close the access site through the skin, where the islet cells are injected. The sandwich technique is so-called because of the layered applications of gelfoam and coil used to close the access site."

Dr. Krishnamoorthy said that even though percutaneous islet cell transplantation is currently an experimental procedure, the sandwich closure is a safe method that prevents many of the complications common to previous techniques used to transplant islet cells. Thirty days after the pr ocedure, all 13 patients were producing insulin without requiring supplemental injections, and none experienced major complications. Liver function tests and blood cell counts were monitored carefully during this time.

In the future, Dr. Krishnamoorthy looks toward the potential use of stem cells for this purpose, and also the development of better immunosuppressive medications to keep the body from rejecting the transplanted islet cells.

Type 1 diabetes, formerly known as juvenile diabetes, is a debilitating disease that is usually diagnosed in children and young adults. It can result in significant morbidity, causing vision loss, loss of sensation that results in severe infections, fractures and amputations, destruction of major organ function (e.g., the kidneys) and cardiovascular disease that can result in complications such as heart attacks. Both genetic and environmental factors contribute to the disease.


'"/>

Source:Radiological Society of North America


Related biology news :

1. Monkeying around to improve organ transplantation
2. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
3. Guiding principles for facial transplantation unveiled
4. Plastic surgeons countdown first full facial transplantation
5. Successful transplantation from pig embryos to mice
6. Researchers create genetically matched embryonic stem cells for transplantation
7. New lab technique identifies high levels of pathogens in therapy pool
8. Brain-mapping technique aids understanding of sleep, wakefulness
9. Study reveals new technique for fingerprinting environmental samples
10. Researchers pioneer new gene therapy technique using natural repair process
11. Newer imaging techniques may lead to over-treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: